193 related articles for article (PubMed ID: 34117307)
21. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
22. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
23. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW; Tshering G; Na-Bangchang K
J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418
[TBL] [Abstract][Full Text] [Related]
24. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
[TBL] [Abstract][Full Text] [Related]
25. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study.
Eltalal S; El Ayouty M; El-Said A; Wahba Y
Acta Neurol Belg; 2021 Dec; 121(6):1623-1631. PubMed ID: 32683556
[TBL] [Abstract][Full Text] [Related]
26. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
27. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.
He L; Chen S; Li J; Xie X; Huang L; Kuang Y; Xu K; Huang W; Zhao Y; Yang G; Guo C
Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1659-1663. PubMed ID: 32469422
[TBL] [Abstract][Full Text] [Related]
28. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
[TBL] [Abstract][Full Text] [Related]
29. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
30. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
31. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
[TBL] [Abstract][Full Text] [Related]
32. Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4.
Yoo SE; Yi M; Kim WY; Cho SA; Lee SS; Lee SJ; Shin JG
Drug Metab Pharmacokinet; 2019 Jun; 34(3):201-208. PubMed ID: 30992242
[TBL] [Abstract][Full Text] [Related]
33. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
Ganoci L; Božina T; Mirošević Skvrce N; Lovrić M; Mas P; Božina N
Drug Metab Pers Ther; 2017 Mar; 32(1):11-21. PubMed ID: 28272018
[TBL] [Abstract][Full Text] [Related]
36. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations.
Zuo LJ; Guo T; Xia DY; Jia LH
Genet Test Mol Biomarkers; 2012 Feb; 16(2):102-8. PubMed ID: 22224559
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.
McGrane IR; Loveland JG
J Child Adolesc Psychopharmacol; 2016 May; 26(4):395-9. PubMed ID: 26871369
[TBL] [Abstract][Full Text] [Related]
38. Rapid screening for targeted genetic variants via high-resolution melting curve analysis.
Chambliss AB; Resnick M; Petrides AK; Clarke WA; Marzinke MA
Clin Chem Lab Med; 2017 Mar; 55(4):507-516. PubMed ID: 27732553
[TBL] [Abstract][Full Text] [Related]
39. Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.
Tayeb HT; Bakheet DH; Zaza K; Wakil SM; Dzimiri N
J Pharm Pharmacol; 2015 Jul; 67(7):972-9. PubMed ID: 25684066
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia.
Jakovski K; Nestorovska AK; Labacevski N; Dimovski AJ
Pharmazie; 2013 Nov; 68(11):893-8. PubMed ID: 24380239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]